Knight Therapeutics Inc (GUD):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Knight Therapeutics Inc (GUD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8308)・商品コード:DATA904C8308
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:59
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Knight Therapeutics Inc (Knight Therapeutics) is a specialty pharmaceutical company focused on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. Its consumer health products are used in the treatment of metabolic diseases, dermatological ailments, osteoarthritis, and pain associated with diabetic and peripheral neuropathy, among others. Knight Therapeutics offers medical devices for prostate ablation surgery and detection of peripheral arterial disease. The company develops drugs for treatment of various therapeutic areas such as bacterial conjunctivitis, oesophageal cancer, endobronchial cancer, diabetic macular edema, opioid addiction, and chronic pain and inflammation, among others. It partners with other companies to sell their products. Knight Therapeutics is headquartered in Montreal, Quebec, Canada.

Knight Therapeutics Inc (GUD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Knight Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Knight Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Knight Therapeutics Acquires ATryn and Photofrin from Orphan Canada 14
Partnerships 16
3D Signatures and Plicit Capital Enters into Licensing Agreement with Knight Therapeutics 16
Knight Therapeutics Enters into Licensing Agreement with Pro Bono Bio 17
Knight Therapeutics Expands Distribution Agreement with Ember Therapeutics 18
Knight Therapeutics Enters into Distribution Agreement with Akorn 19
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 20
Licensing Agreements 21
Knight Therapeutics Enters into Licensing Agreement with Jaguar Health 21
Knight Therapeutics Enters into Licensing Agreement with TherapeuticsMD 22
Knight Therapeutics Enters into Licensing Agreement with Ardelyx 23
Knight Therapeutics Enters into Licensing Agreement with AstraZeneca for Movantik 24
SIFI Enters into Licensing Agreement with Knight Therapeutics 25
Knight Therapeutics Enters into Licensing Agreement with Medimetriks Pharma 26
Knight Therapeutics Enters into Licensing Agreement with Braeburn Pharma for Probuphine 27
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 28
Knight Therapeutics Enters into Licensing Agreement with 60 Degrees Pharma 29
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 30
Knight Therapeutics Enters into Licensing Agreement with Advaxis 31
Equity Offering 32
Knight Therapeutics to Raise USD65 Million in Private Placement of Shares 32
Knight Therapeutics Raises USD176 Million in Public Offering of Shares 34
Advaxis Raises USD25 Million in Private Placement of Shares 36
Knight Therapeutics Raises USD76.5 Million in Public Offering of Shares 38
Knight Therapeutics Completes Private Placement Of Warrants For US$160 Million 39
Asset Transactions 40
Synergy Strips to Acquire US Rights of Neuragen from Knight Therapeutics for USD1.2 Million 40
Acquisition 41
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 41
Knight Therapeutics Acquires 16% of Stake in Pediapharm 42
Knight Therapeutics Acquires 28.3% Stake in Medison Biotech for USD60.3 Million 43
Knight Therapeutics Acquires NeurAxon for USD1.5 Million 44
Knight Therapeutics Inc – Key Competitors 45
Knight Therapeutics Inc – Key Employees 46
Knight Therapeutics Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
May 10, 2018: Knight Reports First Quarter 2018 Results 48
Mar 15, 2018: Knight Reports 2017 Fourth Quarter and Year End Results 49
Nov 09, 2017: Knight Reports Third Quarter 2017 Results 51
Aug 10, 2017: Knight Reports Second Quarter 2017 Results 53
May 11, 2017: Knight Reports First Quarter 2017 Results 55
Mar 16, 2017: Knight Reports Fourth Quarter and Year-Ended December 31, 2016 Results 56
Corporate Communications 57
Oct 10, 2017: Knight Announces Changing of the Finance Guard 57
Feb 23, 2017: Knight Therapeutics Announces Board Change 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Knight Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Knight Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Knight Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Knight Therapeutics Acquires ATryn and Photofrin from Orphan Canada 14
3D Signatures and Plicit Capital Enters into Licensing Agreement with Knight Therapeutics 16
Knight Therapeutics Enters into Licensing Agreement with Pro Bono Bio 17
Knight Therapeutics Expands Distribution Agreement with Ember Therapeutics 18
Knight Therapeutics Enters into Distribution Agreement with Akorn 19
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 20
Knight Therapeutics Enters into Licensing Agreement with Jaguar Health 21
Knight Therapeutics Enters into Licensing Agreement with TherapeuticsMD 22
Knight Therapeutics Enters into Licensing Agreement with Ardelyx 23
Knight Therapeutics Enters into Licensing Agreement with AstraZeneca for Movantik 24
SIFI Enters into Licensing Agreement with Knight Therapeutics 25
Knight Therapeutics Enters into Licensing Agreement with Medimetriks Pharma 26
Knight Therapeutics Enters into Licensing Agreement with Braeburn Pharma for Probuphine 27
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 28
Knight Therapeutics Enters into Licensing Agreement with 60 Degrees Pharma 29
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 30
Knight Therapeutics Enters into Licensing Agreement with Advaxis 31
Knight Therapeutics to Raise USD65 Million in Private Placement of Shares 32
Knight Therapeutics Raises USD176 Million in Public Offering of Shares 34
Advaxis Raises USD25 Million in Private Placement of Shares 36
Knight Therapeutics Raises USD76.5 Million in Public Offering of Shares 38
Knight Therapeutics Completes Private Placement Of Warrants For US$160 Million 39
Synergy Strips to Acquire US Rights of Neuragen from Knight Therapeutics for USD1.2 Million 40
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 41
Knight Therapeutics Acquires 16% of Stake in Pediapharm 42
Knight Therapeutics Acquires 28.3% Stake in Medison Biotech for USD60.3 Million 43
Knight Therapeutics Acquires NeurAxon for USD1.5 Million 44
Knight Therapeutics Inc, Key Competitors 45
Knight Therapeutics Inc, Key Employees 46
Knight Therapeutics Inc, Subsidiaries 47

List of Figures
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Knight Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Knight Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

★調査レポート[Knight Therapeutics Inc (GUD):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8308)販売に関する免責事項を必ずご確認ください。
★調査レポート[Knight Therapeutics Inc (GUD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆